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Blunted peripheral tissue responsiveness to thyroid hormone in uremic
patients. To understand the biologic significance of the low triiodothy-
ronine (T1) syndrome in patients with chronic renal failure (CRF), we
examined thyroid hormone profile, basal 02 uptake (V02), and periph-
eral blood mononuclear leukocyte (PBL) ouabain binding in these
patients and in the control subjects before and after L-triiodothyronine
(T3) and sodium ipodate treatment. In the controls (N = 8), T3
administration increased serum total T3 from 136 15 to 232 11 ng/dl,
and reduced total thyroxine (T4) from 8.14 0.56 to 6.08 0.43 p.gldl,
free T4 from 1.59 0.12 to 1.03 0.05 ngldl and thyroid—stimulating
hormone (TSH) from 1.74 0.24 to 0.41 0.09 tU/ml. V02 increased
from 2.66 0.11 to 3.15 0.09 mI/kg/mm. Ipodate treatment, on the
other hand, resulted in a reduction of serum total L to 102 21 ng/dl,
an increase in total T4 (09.59 0.50 j.g/dl, free T4 to 1.91 0.13 ng/dl
and TSH to 3.64 1.14 jU/ml. V02 decreased to 2.43 0.06
mI/kg/mm. P values ranged from <0.05 to <0.001. In the CRF patients
(N = 14), T3 treatment also resulted in a rise in serum total T3 from 75
5 to 185 8 ng/dl. Total T4 declined from 6.68 0.34 to 5.18 0.48
jg/dl, free T4 from 0.85 0.lto 0.67 0.08 ng/dl and TSH from 3.67
0.86 to 0.94 0.3 U/ml. V02, however, did not change (from 2.91
0.12 to 2.99 0.17 mI/kg/mm). Ipodate treatment decreased total T3
to 65 5 ngldl, and increased total T4 to 8.47 0.52 sgjdl, free T4 to
1.19 0.15 ng/dl, and TSH to 9.82 2.57 .tU/ml. V02 remained
unchanged and was 2.88 0.2 mI/kg/mm. P values, comparing before
and after treatment data, were not significant for V02, but ranged from
<0.05 to <0.001 for thyroid hormones and TSH. PBL ouabain binding
were 0.99 0.22, 0.53 0.10, and 0.43 0.05 pmol/l07 cells,
respectively, in the control (N = II), CRF (N = 9), and hypothyroid
patients (N = 3). T3 treatment failed to correct the ouabain binding
deficiency (0.55 0.06 pmole/l07 cells) in the CRF patients even though
serum TT3 was restored to normal level. The blunted V02 response to
T3 and ipodate and the total lack of correlation between serum T3, T4
and V02 in CRF patients suggest that T3 is not the prime regulator of
thermogenesis in these individuals. The pituitary, however, remained
sensitive as serum TSH was suppressed by T3 and stimulated by
ipodate.
Although it is widely recognized that patients with chronic
renal failure (CRF) have low serum thyroid hormones, their
metabolic status, however, remains unclear [1—3]. Theoreti-
cally, one would expect them to be hypometabolic because
thermogenesis is an important biologic effect of thyroid hor-
mones. On the one hand, actual measurement of basal meta-
bolic rate in the CRF patients as reported by Spector et al was
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normal [4]. On the other hand, data from the uremic rats suggest
the presence of a hypothyroid state at the tissue level [5]. To
reconcile these discrepancies, we undertook a study in which
basal oxygen uptake (V02), peripheral blood mononuclear
leukocyte (PBL) ouabain binding, and serum thyroid hormones
were measured in CRF patients in the basal state and during
periods of L-triiodothyronine (T3) and sodium ipodate treat-
ment. It should be emphasized that basal oxygen uptake (V02),
measured with the modern computerized technique is accurate,
reproducible, and reflects closely thyroid hormone activity in
normal subjects [61. The reason for measuring PBL ouabain
binding stemmed from the report of Arnott, White and Jerums
showing reduced PBL ouabain binding in patients with
hypothyroidism [7]. Assessment of TSH response was done
because Wehmann et al suggested that pituitary TSH secretion
was impaired in patients with non-thyroidal illness [8]. We
wondered if the low thyroid state in the CRF patients might not
also be on the basis of inadequate TSH response.
Essentially we found that V02 bore no relationship to serum
T3 concentration in the CRF patients as alteration of serum T3
with either T3 or sodium ipodate failed to change V02. Simi-
larly, T3 treatment also failed to normalize ouabain binding in
peripheral blood mononuclear leukocytes. On the other hand,
TSH was readily suppressed by T3 and stimulated by ipodate.
These data, thus, suggest an altered sensitivity to thyroid
hormone in the peripheral tissue, but the pituitary remained
responsive.
Methods
Experimental design
Thyroid hormone concentrations, TSH and basal oxygen
uptake (''O2) were compared in 14 CRF patients and eight
normal controls. Studies were performed in the basal state and
during periods of T3 (CytomeV), and sodium ipodate
(OragrafinR) treatment. L-triiodothyronine was designed to
raise serum T1 concentration, and ipodate, an oral cholecyto-
graphic agent which inhibits T4 to T3 conversion, to decrease
serum T3. The sequence of the three periods was randomized
and a minimum two—week "washout" period was observed
between different treatments. T3 was given at a dose of 0.8
tg/kgIday divided into three or four equal doses orally and I g
of ipodate was given orally per day. The duration of treatment
of both T3 and ipodate was variable. Four control subjects
received T3 and ipodate for 14 days and the other four, three
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days. Of the 14 CRF patients, seven received T3 and ipodate for
14 days, four for seven days, and the remaining three, three
days. Since the changes in 'O2 and TSH were statistically not
different with the various regimens of treatment, data were
analyzed as a group. In the four controls and seven CRF
patients who received T3 and ipodate for 14 days, V02 was
measured twice for each period (basal, T3, and ipodate) during
the second week of treatment to determine the coefficient of
variation of the method. For those who received treatment for
seven days, 'O2 was usually measured on the fifth day. For
those who received treatment for three days, VO2 was mea-
sured on the fourth day; an extra dose of T3 was given about
two hours before the measurement. Blood for determination of
thyroid hormones and TSH was obtained in the basal state and
at the end of each treatment period approximately two to three
hours after the last dose of T3. Additionally, PBL ouabain
binding kinetics was examined in 11 normal subjects (all eight of
those who participated in the 'O2 protocol and three who did
not), nine CRF patients (all of them took part in the VO2 study)
and three hypothyroid patients (documented by low serum TT4,
FT4, and TT3 and elevated serum TSH). In seven of the nine
CRF patients, ouabain binding study was repeated after T3
treatment.
Subjects
All 14 patients were in our chronic maintenance dialysis
program; 11 were on hemodialysis and three were being treated
with chronic ambulatory peritoneal dialysis. The hemodialysis
patients were dialyzed three times a week using standard
dialysis procedures and dialyzers. Their age ranged from 21 to
65, and the mean age was 47.1 4.2. There were seven males
and seven females. The serum urea nitrogen (rng/dl) and creat-
mine (mgldl) were, respectively, 77.5 6.3 (ranging from 51 to
106) and 12.1 0.7 (ranged from 8.8 to 16.7). All patients were
judged to be in satisfactory nutritional status. Mean serum
albumin (g/dl) was 3.8 0.2, mean body weight (kg) was 65.2
2.9, and mean body mass index [wt (kg)/Ht (rn)2] was 25.0
1.4. All participants were clinically stable and without any
intercurrent illness. Subjects with congestive heart failure,
angina and diabetes mellitus were excluded. All patients re-
ceived aluminum—containing phosphate binder, multivitamins,
folate, pyridoxine and iron supplements. One patient was taking
Propanolol for mild hypertension. The eight normal control
subjects consisted of four males and four females. Their age
ranged from 25 to 60, and the mean age was 39.1 4.2. The
mean body weight and body mass index were, respectively,
73.8 6.9 and 24.4 1.2. None of them were taking any
medication. The age, body weight and body mass index were
not different statistically between the patients and the controls.
Serum thyroid hormone profile
Serum total thyroxine (TT4), free T4 (FT4) and total triiodo-
thyronine (TT3) concentrations were measured by radioim-
munoassays using commercially available kits (Clinical assays,
Cambridge, Massachusetts, USA). Serum free T4 was deter-
mined by a two—step competitive assay in which the sample was
first incubated with the antibodies immobilized in the tube; this
was followed by a second incubation with tracer T4. The
standard curve ranged from 0.18 2.5 ng/dI. Serum TSH was
measured with the Serono (Braintree, Massachusetts, USA)
kits using an immunoradiometric technique [9]. There were two
1251 labeled monoclonal antibodies and a third monoclonal
antibody coupled to fluorescein isothiocyanate (FITC). This
assay has excellent sensitivity, detecting levels as low as 0.1
U/ml. Normal value (mean SEM) in our laboratory is 1.42
0.10 [6].
Basal oxygen uptake (%O2)
Oxygen uptake ('O2) and carbon dioxide production ('CO2)
were determined as previously described with the MGC Exer-
cise System 2000 (Medial Graphic Corp., St. Paul, Minnesota,
USA). This system provides a breath—by—breath analysis of
many variables including VO2, VCO2, and VE, heart rate and
their derivatives [6, 10, 11].
During the test, a mouth piece attached to a two-way valve
(dead space 60 ml) was used. Expired gas from each breath was
sampled by a small gas line leading from the mouthpiece to the
rapid responding 02 and infra-red CO2 analyzers; 100 samples
per second were analyzed. Simultaneously, tidal volume and
frequency of respiration were measured by a Hans Rudolph
pneumotachograph, model 3800 (Hans Rudolph, Inc., Kansas
City, Missouri, USA) positioned in the expiratory line. Mea-
surements were taken continuously for 10 minutes and standard
equations were used to calculate V02 and 'CO2, STPD.
and
02 = F102 x — FEO2 X VE
CO2 = FECO2 X Vp.
F1O2 and FEO2 represent % 02 in the inspired and expired gas,
respectively, and FECO7, % CO2 in the expired gas. V1 and VE
are inspiratory and expiratory volumes. The volume of F1C02
was too small in the basal state to be accounted for.
During the 10 minute period of testing, the expired gas was
collected for quality control in a 120-liter Douglas bag, and its
'p02 and ''CO2 were determined separately using the same
analyzers which had previously undergone quality control by
calibration against other analyzers in our laboratory.
Isolation of peripheral blood mononuclear leukocytes (PBL)
and ouabain binding assay
Venous blood, 40 to 60 ml, was drawn into commercially
prepared EDTA tubes. After mixing with two volumes of 0.9%
saline, the blood—saline mixture was underlaid with Histopaque
(Sigma, St. Louis, Missouri, USA, specific gravity 1.077) and
centrifuged at 400 x g, 20°C for 45 minutes. Mononuclear cells
harvested from the Histopaque—plasma interface were washed
once with saline and a second Histopaque gradient centrifuga-
tion was done to totally eliminate the red blood cells. Mononu-
clear leukocytes, recovered from the interface, were again
washed twice with saline. In the second wash, the volume was
adjusted to exactly 10 ml from which a small aliquot (20 p1) was
taken for cell Count using the Coulter Counter (Coulter Elec-
tronic Inc., Hialeah, Florida, USA). Following the last wash,
the cell pellets were then suspended in a desired volume of
phosphate buffered saline, varying from 1.0 to 1.5 ml. For
ouabain binding, tubes were set up for each concentration of
unlabeled ouabain ranging from 0 to 100 n (all molality in this
section refers to that of the final concentration). At least six
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Table 1. Serum thyroid hormone profile in control subjects and chronic renal failure (CRF) patients in the basal state and during
L-triiodothyronine and ipodate treatment°
Group/period TT4 pg/dl FF4 ng/dl TT3 ng/dl TSH U/m!
Control (N = 8) Basal
T3
Ipodate
pb
CRF (N = 14) Basal
T3
Ipodate
Pb
8.14 0.56
6,08 0,43d
9.59 0.50
<0.001
6.68 0,34S
5.18 0,48'
8.47 0.52e
<0.001
1.59 0.12
1.03 0.05
1.91 0.13
<0.001
0.85 0.l0
0.67 0.08e
1.19 0.15
<0.01
136 15
232 11'
102 21
<0.001
75 Sf
185 8'
65 5'
<0.001
1.74 0.24
0.41 009d
3.65 1.14
<0.01
3.67 0.86
0.94 030d
9.82 2.57°
<0.001
a All values are means SEM. TI'4, Fl'4, TI'3 and TSH represent, respectively, total thyroxine, free thyroxine, total triiodothyronine and thyroid
stimulating hormone in the serumbp values derived from analysis of variance testing the significance of the differences between all 3 study periods within the same group
C I and e represent, respectively, P values of <0.001, <0.005 and <0.01 comparing each experimental period to its respective basal value within
the same group by paired i-test
1and g representP <0.001 and <0.05 testing the differences of the values in the basal state between the 2 groups of subjects using Student's i-test
points were used per assay, usually eight. Each tube, in
addition to SO pi of unlabeled ouabain, contained 50 s1 of
3H-ouabain (SA 18 Ci/mole, 5.3 nr'i, New England Nuclear,
Billerica, Massachusetts, USA), 250 Hepes buffer (pH 7.45),
50 l of Tris-ATP (3 nM, Sigma), and 100 pi of cell suspension.
Non-specific binding was estimated by parallel incubation with
an excess amount of unlabeled ouabain (0.5 SM). All the tubes
were incubated at 37°C in a shaking water bath for 90 minutes.
The entire incubate from each tube was transferred to a
microfuge tube, overlayed with 0.8 ml of Hepes buffer, and
centrifuged in an Eppendorf centrifuge at 4°C for four minutes.
The supernatants were discarded and the tightly packed pellets
were solubilized with 500 l of Soluene 350 (Packard Instru-
ment Co., Downers Grove, illinois, USA) overnight at room
temperature. Following solubilization, scintillating cocktail was
added to each sample. The vials were vortexed and maintained
at 4°C for two to three hours and the radioactivity determined in
a Packard Scintillation Counter (Packard Tri-Carb 4530) [7, 12,
13].
In the 11 control subjects, mean total counts (cpm) in the tube
was 16,175 331. The counts in the tubes where no unlabeled
ouabain were added averaged 927 113. The counts in the
tubes where excess amount (0.5 LM) of unlabeled ouabain were
added (non-specific tubes) averaged 83 8. Thus, 5.73% of
tracer were bound before carrying out displacement studies,
and the non-specific binding was 8.95%.
Statistical analysis
All data were presented as means SEM. Student's and
paired i-tests, analysis of variance, and linear regression anal-
ysis were performed using the Clinfo System of the Clinical
Research Center of the University of Iowa College of Medicine.
Protocol approval
Informed written consent was obtained from every partici-
pant. The protocols were approved by the Clinical Research
Center Committee and the Committee on Research Involving
Human Subjects of the University of Iowa Hospitals and
Clinics and the Veterans Administration Medical Center of
Iowa City.
Results
Thyroid hormone profile
Table 1 summarizes thyroid hormone profile in the controls
and the CRF patients before and after T3 and ipodate treatment.
In the basal state, TT4, FT4, and TT3 were significantly lower in
the CRF patients; TT4 and FT4 were reduced to 82% and 63%,
respectively, of the control levels, and TT3 was reduced to 56%
of the control value. In contrast, serum TSH was not different
between the two groups. T3 administration increased serum
TT3, and reduced serum TT4, FT4 and TSH while ipodate
treatment reduced serum TT3, and increased TT4, FT4 and TSH
in both groups of subjects. The magnitude of change with regard
to T4 and T3 was comparable. While TSH was equally sensitive
to T3 suppression in both groups, its response to ipodate
appeared to be exaggerated in the CRF patients; mean frac-
tional increment was 167% as compared to 109% in the con-
trols.
Basal oxygen uptake (%O) and other parameters of
respiration
Despite wide variability of 'O2 from person to person,
repeated measurements in the same individual were reproduc-
ible. This was equally true in controls as well as in CRF
patients. The coefficients of variation (mean 5EM) of V02
were 4.18 1.24%, in the controls and and 6.11 1.43% in the
CRF patients.
Table 2 compares 'O2, respiratory exchange ratio
('CO2IVO2), minute ventilation (VE), end—tidal parital pressure
of CO2 (PETCO2) and oxygen extraction (''02/"E, or ml of 02
consumed per liter of minute ventilation) in the control and the
CRF patients. In the basal state, "02 was not statistically
different between the controls and the CRF patients. End tidal
pressure of CO2 was lower, minute ventilation higher, and
oxygen extraction (°O2I'E) reduced in CRF patients. After T3
administration V02 and 'C02 increased in the controls while
the respiratory exchange ratio, VCO2/VCO2, remained un-
changed. Minute ventilation was slightly, though not signifi-
cantly, increased. End tidal partial pressure of CO2 as well as
02 extraction were unaffected. By contrast, VO2 and VCO2, as
well as all other parameters of respiration, were not altered in
the CRF patients after T3 treatment. Following ipodate admin-
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Table 2. Oxygen uptake, respiratory exchan
stat
ge ratio and minute ventilation in normal subjects and ch
e and during L-triiodothryonine and ipodate treatmenta
ronic renal failure patients in the basal
Group/period V02 mi/kg/mm VCO2/V02 PETCO2 mm Hg VE liter/mm V02/VE mi/liter
Control Basal
T3
Ipodate
pb
CRF Basal
T3
Ipodate
pb
2.66 0.11
3.15 0.09C
2.43 0,06d
<0.001
2.91 0.12
2.99 0.17
2.88 0.09
NS
0.88 0.03 38.3 0.9
0.92 0.02 38.5 1.1
0.91 0.03 39.7 0.8
NS NS
0.90 0.02 32.5 l.0
0.94 0.03 33.1 0,8
0.94 0.12 33.1 1.6
NS NS
6.44 0.67
7.33 0.85
6.29 0.77
NS
7.95 0.55
8.41 0.74
8.58 1.06
NS
30.9 I.!
32.6 1.8
29.8 1.6
NS
24.4 l.le
23.7 1.0
22.8 1.9
NS
Values are presented as mean SEM. V02, 'CO2/VO2, PETCO2, VE, and VOz/VE represent, respectively, oxygen uptake, respiratory
exchange ratio, end tidal partial pressure of CO2. minute ventilation, and oxygen extraction (ml of 02 extracted from minute ventilation)b P values derived from analysis of variance testing the significance of the differences between all 3 study periods within the same group
C and d represent, respectively, P values of <0.001 and <0.005 comparing each experimental period to its respective basal value within the same
group by paried t-test
P < 0.001 testing the differences of the values in the basal state between the 2 groups using Student's t-test
Table 3. Peripheral blood mononuclear leukocyte ouabain binding in normal subjects and patients with chronic renal failure and hypothyroidism
Group N
Serum TT3
ng/dl
C,,ax
pmole/107 cells Kd X 109M
Control 11 126 4 0.99 0.22 29.4 5.6
CRF 9 79 5a 0.53 010b 24.9 5.2
Hypothyroid 3 41 l1 0.43 0.05' 19.4 2.7
CRF + T3 7 156 14C 0.55 0.06 22.9 5.1
Values are presented as means SEM. CRF and CRF T3 represent, respectively, patients with chronic renal failure and the same patients
treated with 50 pg/day of L-triiodothyronine. Cmax and Kd are, respectively, maximal ouabain binding capacity and dissociation constant. The
significance of the differences between CRF and hypothyroid patients versus the controls was assessed by Student's t-test
a p <0.001
b p < 0.05
P < 0.001, the difference between CRF and CRF T3 was also assessed by Student's t-test.
A
12
10
8
0.
I;
____________0
istration, 'O2 decreased in the control subjects but remained
unchanged in the CRF patients.
Peripheral blood mononuclear leukocyte ouabain binding
Incubation of 3 x 106 cells with a constant amount of
3H-ouabain and increasing concentrations of unlabeled ouabain
resulted in a progressive rise in bound ouabain, reaching a
maximum when the total ouabain concentration was about 80
nM, thereafter, the binding plateaued, indicating that ouabain
binding to the PBL was saturable.
Ouabain binding data are summarized in Table 3. Maximal
ouabain binding capacity (Cmax)varied widely in all groups, but
the mean values of the CRF and the hypothyroid patients were
significantly lower than that of the controls. The dissociation
constant (Kd), however, was not different. More importantly,
T3 administration to the CRF patients failed to restore PBL
ouabain binding capacity despite normalization of serum T3.
Furthermore, there was no correlation between serum TT3 and
ouabain binding capacity in the CRF patients (N = 16, r = 0.06,
P = 0.82).
Correlation between serum thyroid hormones and 02 uptake
Figure 1 compares the frequency distribution of serum TT3
and 02 uptake in 18 controls and 17 CRF patients. It should be
mentioned that 10 control subjects and three CRF patients had
'02 and thyroid hormone profile determined only in the basal
Control
B
7
6
5
4
3
2
.0
0 50 100 150 200 250 2
Serum TT3, ng/dI
2.5 3 3.5 4
VO, mi/kg/mm
Fig. 1. Frequency distribution of serum TT3
(A) and 1'O2 (B) in 18 control subjects (—•)
and 17 CRF patients (O---O).
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Fig. 2. Changes in serum TT3 (A) and 'O2 'B) in control subjects and
CRFpatients during T3 and Ipodate treatment as compared to the basal
values (B).
state without undergoing the experimental procedures of T3 and
ipodate treatment. Thus, the number of subjects are different
between Figures 1 and 2, and between Figure 1 and Tables 1
and 2. There is a distinct separation of serum TT3 between the
two groups; 16 of 18 normals had serum TI'3 > 100 ngldl,
whereas 15 of 17 CRF patients had serum TT1 < 100 ng/dl (Fig.
IA). By contrast, the distribution of V02 is not different
between the two groups (Fig. 1B). Figure 2A depicts changes in
serum TT3 during T3 and ipodate treatment in the controls and
the CRF patients. In both groups of subjects, T3 predictably
raised and ipodate uniformly lowered serum T3. Figure 2B
demonstrated changes in 'O2 during treatment. In every con-
trol subject, T3 increased while ipodate reduced V02. By
contrast, in CRF patients, eight of 14 subjects showed either
decrease or no change in 'O2 during T3 treatment and only two
of eight showed a decrease in ''O2 following ipodate adminis-
tration.
Table 4 summarizes and compares the regression analyses
between 'O2 and serum TT3, TT4, and FT4 in the control
subjects and in the CRF patients. Values obtained in the basal
Variable r F-Ratios P
Multiple correlation coefficients
Control (N = 25)
Rl.234 0.821 14.43 0.001
R1.23 0.811 21.07 <0.0001
RI.24 0.819 22.38 <0.0001
R1.34 0.655 8.27 0.002
CRF (N = 33)
R1.234 0.334 1.212 0.355
Rl.23 0.297 1.456 0.249
Rl.24 0.249 0.993 0.382
R1.34 0.289 1.365 0.271
Single correlation coefficients
Control (N = 25)
R1.2 0.747 29.03 0.001
Rl.3 —0.518 8.42 0.008
RI.4 —0.650 16.86 0.001
CRF (N = 33)
R1.2 0.249 2.04 0.163
Rl.3 —0.244 1.97 0.171
R1.4 —0.041 0.05 0.822
state as well as those obtained during T3 and ipodate treatment
periods were included in the analysis. Note that the correlation
coefficients between V02 and serum thyroid hormones, taken
collectively or singly, were highly significant in the controls. By
contrast, none of the correlation coefficients was significant in
the CRF patients.
The negative correlations between V02 and TT4, as well as
02 and PT4, should not be taken to mean that high serum T4
inhibited tissue 02 uptake. Due to the nature of our experimen-
tal design, serum T4 and T3 changed in opposite directions.
After T3 treatment, serum T3 increased and T4 declined; 'O2
rose. Following ipodate administration, while serum T3 de-
clined, T4 rose; ''02 decreased. The changes in 02 correlated
positively with T3 and, therefore, negatively with T4.
Discussion
In the present study, we found that despite low serum thyroid
hormone concentrations, CRF patients had normal 02 uptake.
More importantly, their response to thyroid hormone with
regard to thermogenesis was blunted. Of the 14 patients given
T3, eight failed to raise their Similarly, following ipodate
administration, only two showed a decrease in ''O2. This
pattern of response is unequivocally different from those of
normal subjects whose V02 was predictably increased by T3
and uniformly suppressed by ipodate.
Normal oxygen uptake in the CRF patients whose serum T4
and T3 were reduced is an unexpected finding; we were antic-
ipating a lower 'O2 because normal subjects undergoing star-
vation lower their serum T3 and predictably also reduce their
'O2 {14, 15].
It is unlikely that the failure of ''02 to increase during T3
administration in patients with renal insufficiency is due to their
medication. Among the drugs being taken, only beta—blocker is
Control (n=8) CRF(n=14)
Table 4. Correlation between oxygen uptake and serum thyroid
hormones in control subjects and chronic renal failure patientsA
300
200
I-I-
£
a,
100
0
B
4
3
2
a R refers to variables; I, 2, 3, and 4 represent V02, TT1, TT4, and
FT4, respectively. RI, V02, is the dependent variable, and the others,
R2, 3,4 are independent variables. The results of the multiple as well as
single linear regression analysis are presented as r, (correlation coeffi-
cients), F ratios and P values.
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known to blunt the metabolic effects of thyroid hormone [161.
Of the 14 patients whom we studied, only one was taking small
doses of Propranolol (20mg bid), and these doses were held for
24 hours before VO2 measurement. Hypo-responsiveness to
thyroid hormone has been reported by Wimpfheimer et al in
starving rats; five to 10 times higher doses ofT3 are needed to
elicit a comparable rise in ''O2 as compared to the fed rats [17].
It also seems unlikely that this is the explanation for the lack of
response seen in our patients because they were neither starved
nor poorly nourished. In fact, their nutritional status was not
different from the controls as supported by the normal serum
albumin level as well as normal body weight and body mass
index. Thus, we came to the inevitable conclusion that the
failure of ''O2 to rise following T3 administration represents
some degree of tissue resistance.
The reason for such hypo-responsiveness is not clear. One
possibility would be a reduction in T3 receptors. Our previous
studies showing a decreased hepatic nuclear T3 binding capac-
ity in the uremic rat model are in agreement with this hypothesis
[18]. Recent work by Kinlaw et al, however, failed to confirm
the reduction in nuclear T3 content in a similar rat model [191.
It should be emphasized that our data were obtained by in vitro
incubation of purified hepatic nuclear T3 receptors and
scatchard analysis whereas Kinlaw and colleagues calculated
nuclear T3 content from the product of plasma T3 concentration
and hepatic nuclear/plasma ratio of [1251] T3 which was injected
in vivo with and without an accompanying loading dose of
unlabeled T3.
The reduced ouabain binding in the CRF and hypothyroid
patients suggests that Na-K ATPase activity was reduced.
Although we did not measure Na-K ATPase in the PBL, there
is abundance of literature attesting to the close parallelism
between Na-K ATPase activity and ouabain binding, the latter
being proportional to the number of enzyme molecules [13, 20,
211, The fact that intracellular sodium concentration is fre-
quently increased in the red blood cells and leukocytes of CRF
patients corroborates with the concept of decreased Na-K
ATPase activity [22, 23]. In hypothyroid subjects, thyroid
hormone treatment restores ouabain binding capacity [7]. By
contrast, T3 treatment in CRF patients failed to normalize
ouabain binding. Although this could be interpreted as another
manifestation of thyroid hormone resistance, one nevertheless
could not exclude the alternative possibility that uremia per se
may decrease Na-K ATPase activity independent of thyroid
hormone deficiency or resistance. The low 02 extraction (ml
02/liter VE) found in CRF patients does not represent
hypometabolism; it merely reflects increased ventilation (yE).
End tidal pCO2, which correlates closely to pulmonary end
capillary pCO2 at rest, was also lower, again suggesting hyper-
ventilation, most likely secondary to metabolic acidosis.
With regard to TSH secretion, the present data show that
CRF subjects exhibited appropriate changes in serum TSH
following acute alterations in circulating thyroid hormones
induced through pharmacologic maneuvers. Whether serum
TSH is appropriately elevated in the basal state when serum T4
and T3 were significantly reduced is difficult to ascertain.
Comparing thyroid hormone profile of the CRF patients in the
basal state to the control subjects during the ipodate period
(Table I), one finds that while TSH levels are comparable,
serum TT4, FT4, and TT3 are lower in the CRF patients, thus
suggesting that the pituitary—thyroid feedback in these individ-
uals may be re-set at a lower level. Hershman et a! have
previously suggested the possibility of inadequate pituitary
response in patients with renal failure because they have normal
serum TSH despite reduced serum T4 and T3 [24]. Similarly, in
illnesses unrelated to renal insufficiency, Bacci and colleagues
[25], Maturlo and associates [26], and Wehmann et al [8] have
proposed that normal serum TSH in the face of low circulating
thyroid hormones might represent a deviation from normality in
the regulation of TSH secretion.
In summary, the present study demonstrated that, in patients
with renal insufficiency, whole body oxygen uptake and PBL
ouabain binding were not affected by changing serum concen-
trations of thyroid hormones. These could be taken as evidence
suggestive of tissue resistance to thyroid hormone. It is con-
ceivable that altered tissue sensitivity to thyroid hormone may
provide a more efficient control of thyroid hormone effects than
that brought about by changing serum hormone concentrations.
Alternatively, one could postulate that factors present in uremia
may over—ride the effects of thyroid hormone in regulating body
thermogenesis. The pituitary, however, did not share the non-
responsiveness of the peripheral tissue; serum TSH was readily
suppressed by T3 and stimulated by ipodate.
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